Welcome to our dedicated page for Aptargroup news (Ticker: ATR), a resource for investors and traders seeking the latest updates and insights on Aptargroup stock.
AptarGroup, Inc. (NYSE: ATR) generates news across drug delivery, digital health and consumer dispensing technologies. As a global company serving pharmaceutical, beauty, food, beverage, personal care and home care markets, its announcements often highlight new delivery systems, clinical collaborations, acquisitions and financial updates that are relevant to investors and industry observers.
Recent news has featured Aptar Pharma’s nasal and ophthalmic platforms, such as LuerVax and Spray Divider being used in a Phase II clinical trial of an intranasal COVID-19 vaccine candidate, and Bidose liquid nasal spray systems delivering an FDA-approved treatment for paroxysmal supraventricular tachycardia. The company also reports on developments in eye care, including its Beat the Blink technology and preservative-free multidose dispensers, as well as broader portfolios of ophthalmic solutions.
Aptar’s Digital Health division appears frequently in updates related to connected health tools and data-driven care. Examples include the integration of the Migraine Buddy app with biometric data from wearable devices and FDA 510(k) clearance for HeroTracker Sense, a connected add-on for metered-dose inhalers within a respiratory disease management platform.
Investors following ATR news will also find earnings releases, segment performance commentary, conference participation announcements and information on capital markets activity, such as senior notes offerings. This news page brings together these items so readers can review Aptar’s latest product milestones, partnerships, digital health initiatives and financial communications in one place.
Summary not available.
AptarGroup, Inc. (NYSE: ATR) announced the appointment of Julie Xing to its Board of Directors. With over 20 years of experience in sectors like pharmaceuticals and medtech, Julie aims to inspire sustainable growth in challenging markets. She previously served as Executive Chair of Mundipharma China and held various leadership roles at Eli Lilly. Aptar's President and CEO, Stephan B. Tanda, emphasized the value of her insights into the pharmaceutical market, particularly in Asia. The company celebrates diversity on its board, with 45% female representation. Julie holds a Ph.D. in Biology from Hong Kong University.
AptarGroup, Inc. (NYSE:ATR) reported a net income of $59 million for Q4 2022, a 2% year-over-year increase. While reported sales dipped 2% to $796 million, core sales grew 4%, driven by strong performance in the pharma and beauty segments. Adjusted EBITDA fell 4% to $147 million. For the full year, net income decreased 2% to $239 million, but adjusted earnings per share rose 5% to $3.79. The company completed its 29th consecutive year of increasing dividends, with $99 million returned to shareholders in 2022. Aptar anticipates continued momentum in 2023, focusing on efficiencies and growth in key markets.
AptarGroup, Inc. (NYSE: ATR) has once again secured a Platinum rating from EcoVadis, positioning it among the top 1% of over 90,000 companies evaluated across various industries. This recognition highlights Aptar's commitment to sustainability in environmental stewardship, labor rights, ethics, and sustainable procurement.
CEO Stephan B. Tanda stated that this achievement underscores the company's dedication to ethical practices and a circular economy. The EcoVadis rating methodology is based on international sustainability standards, enhancing Aptar’s reputation as a leader in eco-friendly solutions.
Aptar Pharma, a leader in drug delivery systems and part of AptarGroup (NYSE: ATR), has launched the APF Futurity nasal spray pump, the first metal-free, multidose nasal spray designed for over-the-counter formulations. This pump, certified as highly recyclable by cyclos-HTP, minimizes recycling challenges and promotes sustainability. Made from polyolefin materials without metal components, APF Futurity supports the global shift towards eco-friendly products. The innovative design, based on proven technology, delivers consistent dosing without compromising performance. The product will be unveiled at Pharmapack 2023 in Paris on February 1-2, 2023.
AptarGroup (NYSE: ATR) has declared a quarterly cash dividend of $0.38 per share, payable on February 23, 2023, to stockholders of record as of February 2, 2023. Additionally, a conference call is scheduled for February 17, 2023, at 8:00 a.m. CT to discuss the fourth quarter and year-end results for 2022. The company also announced that the 2023 Annual Meeting of Stockholders will take place virtually on May 3, 2023, at 9:00 a.m. CT, with a record date of March 10, 2023. For further details, visit www.aptar.com.
AptarGroup, Inc. (NYSE: ATR), based in Crystal Lake, Illinois, announced its quarterly conference call schedule for 2023. Key dates include:
- Q4 2022 on February 16, 2023 (call on February 17, 2023, at 8:00 a.m. CT)
- Q1 2023 on April 27, 2023 (call on April 28, 2023, at 8:00 a.m. CT)
- Q2 2023 on July 27, 2023 (call on July 28, 2023, at 8:00 a.m. CT)
- Q3 2023 on October 25, 2023 (call on October 26, 2023, at 8:00 a.m. CT)
Press releases will follow after the close of trading on the NYSE.
AptarGroup, Inc. (NYSE: ATR), a leader in drug delivery and consumer product dispensing, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 12:45 p.m. EST. Key executives, including President and CEO Stephan Tanda, will be present. The presentation will be accessible on the company's Investors page. Aptar operates globally, providing innovative solutions for various markets, including pharmaceuticals and beauty. The company is headquartered in Crystal Lake, Illinois, employing 13,000 staff across 20 countries.
Summary not available.
AptarGroup, Inc. (NYSE: ATR) announced a realignment of its business reporting segments, effective January 1, 2023. The new segments, Aptar Closures and Aptar Beauty, aim to streamline operations and enhance customer focus. The Aptar Closures segment will consolidate closures expertise to broaden market reach, while Aptar Beauty will focus on complex dispensing solutions for various markets. The company will continue to report on three segments, including Aptar Pharma, and will disclose recast historical financials prior to its first quarter results.